Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents ...
FDA approves Dupixent for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), expanding from initial approval for adults. Dupixent, a biologic inhibiting IL-4 and IL-13 pathways, demonstrated efficacy in trials, improving nasal congestion, polyp size, and sense of smell, while reducing corticosteroid use and surgery.
Reference News
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents ...
FDA approves Dupixent for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), expanding from initial approval for adults. Dupixent, a biologic inhibiting IL-4 and IL-13 pathways, demonstrated efficacy in trials, improving nasal congestion, polyp size, and sense of smell, while reducing corticosteroid use and surgery.